Key result
Statin therapy mitigates anthracycline-induced cardiotoxicity by preserving LVEF.
Why the study?
Anthracycline-induced cardiotoxicity leads to reduced LVEF and heart failure, and while statins show cardioprotective effects, their effectiveness varies and long-term effects remain unclear due to the lack of a standardized protocol.
Does statin therapy prevent anthracycline-induced cardiotoxicity in patients receiving chemotherapy?
Does statin therapy prevent anthracycline-induced cardiotoxicity in patients receiving chemotherapy?
Statins show promise in mitigating anthracycline-induced cardiotoxicity by preserving LVEF, but further research is needed to establish standardized guidelines for their use.
May support statin co-use with anthracyclines to limit cardiotoxicity; leaves open optimal type, dose, and patient selection.
Several randomized controlled trials (RCTs), animal studies, and observational studies have demonstrated the cardioprotective effects of statins, though their effectiveness varies. The observed variability may be attributed to individual differences, patient ages, disparities in statin type and dosage of anthracyclines (ANT) administered, and variations in cancer conditions among patients. Overall, statins play a beneficial role in reducing oxidative stress and inflammation, enhancing tumor sensitivity to chemotherapeutic drugs, improving mitochondrial function in cardiac cells, exerting antiapoptotic effects, and preserving left ventricular ejection fraction (LVEF). Despite these promising findings, the long‐term effects of statins remain unclear due to the lack of a standardized protocol. Statins may also cause side effects by depleting essential substances in the body. This limitation underscores the need for further research to assess their long‐term impact and establish standardized guidelines for dosing, duration, and potential side effects. The implications of this review highlight the importance of understanding the pleiotropic effects of statins to develop targeted therapies for chemotherapy‐induced cardiotoxicity. Additionally, integrating ongoing research into clinical guidelines is essential, ensuring that clinicians carefully consider patient‐specific factors when prescribing statins alongside ANT. This present review explores the potential role of statins in mitigating ANT‐induced cardiotoxicity, a major complication of chemotherapy that reduces LVEF and leads to heart failure (HF).
No takes yet. Share an insight, caveat, or question.
Mansour et al. (2026) conducted a review in Anthracycline-induced cardiotoxicity. Statin therapy was evaluated. Statin therapy demonstrated beneficial cardioprotective effects against anthracycline-induced cardiotoxicity by preserving left ventricular ejection fraction, though long-term effects remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: